Bleomycin, methotrexate, and streptozotocin in epidermoid carcinoma of the lung: An active drug combination with major nonhematologic toxicity

D. C. Ihde; M. H. Cohen; P. A. Bunn; A. M. Bernath; L. E. Broder; J. D. Minna

Bleomycin, methotrexate, and streptozotocin in epidermoid carcinoma of the lung: An active drug combination with major nonhematologic toxicity

D. C. Ihde, M. H. Cohen, P. A. Bunn, A. M. Bernath, L. E. Broder, J. D. Minna

Research output: Contribution to journal › Article › peer-review

Abstract

Bleomycin (BLM), which produces little hematologic toxicity, and methotrexate (MTX) have reported response rates of 13% and 25% respectively in epidermoid lung cancer. Given together, they induced regressions in 53% of evaluable patients with epidermoid carcinomas. The nitrosoureas CCNU and methyl-CCNU also possess similar single-agent activity in this histologic type of lung tumor. At least a single objective response of non-small cell pulmonary carcinoma to the nonmyelosuppressive nitrosourea streptozotocin (STZ) has been observed. The authors therefore studied the effects of combined therapy with BLM, MTX, and STZ in patients with epidermoid carcinoma of the lung.

Original language	English (US)
Pages (from-to)	155-157
Number of pages	3
Journal	Cancer Treatment Reports
Volume	62
Issue number	1
State	Published - Sep 15 1978

ASJC Scopus subject areas

Oncology
Cancer Research

Cite this

@article{8ba307fbc354484995d86d4f8a26ab72,

title = "Bleomycin, methotrexate, and streptozotocin in epidermoid carcinoma of the lung: An active drug combination with major nonhematologic toxicity",

abstract = "Bleomycin (BLM), which produces little hematologic toxicity, and methotrexate (MTX) have reported response rates of 13% and 25% respectively in epidermoid lung cancer. Given together, they induced regressions in 53% of evaluable patients with epidermoid carcinomas. The nitrosoureas CCNU and methyl-CCNU also possess similar single-agent activity in this histologic type of lung tumor. At least a single objective response of non-small cell pulmonary carcinoma to the nonmyelosuppressive nitrosourea streptozotocin (STZ) has been observed. The authors therefore studied the effects of combined therapy with BLM, MTX, and STZ in patients with epidermoid carcinoma of the lung.",

author = "Ihde, {D. C.} and Cohen, {M. H.} and Bunn, {P. A.} and Bernath, {A. M.} and Broder, {L. E.} and Minna, {J. D.}",

year = "1978",

month = sep,

day = "15",

language = "English (US)",

volume = "62",

pages = "155--157",

journal = "Cancer Treatment Reports",

issn = "0361-5960",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Bleomycin, methotrexate, and streptozotocin in epidermoid carcinoma of the lung

T2 - An active drug combination with major nonhematologic toxicity

AU - Ihde, D. C.

AU - Cohen, M. H.

AU - Bunn, P. A.

AU - Bernath, A. M.

AU - Broder, L. E.

AU - Minna, J. D.

PY - 1978/9/15

Y1 - 1978/9/15

N2 - Bleomycin (BLM), which produces little hematologic toxicity, and methotrexate (MTX) have reported response rates of 13% and 25% respectively in epidermoid lung cancer. Given together, they induced regressions in 53% of evaluable patients with epidermoid carcinomas. The nitrosoureas CCNU and methyl-CCNU also possess similar single-agent activity in this histologic type of lung tumor. At least a single objective response of non-small cell pulmonary carcinoma to the nonmyelosuppressive nitrosourea streptozotocin (STZ) has been observed. The authors therefore studied the effects of combined therapy with BLM, MTX, and STZ in patients with epidermoid carcinoma of the lung.

AB - Bleomycin (BLM), which produces little hematologic toxicity, and methotrexate (MTX) have reported response rates of 13% and 25% respectively in epidermoid lung cancer. Given together, they induced regressions in 53% of evaluable patients with epidermoid carcinomas. The nitrosoureas CCNU and methyl-CCNU also possess similar single-agent activity in this histologic type of lung tumor. At least a single objective response of non-small cell pulmonary carcinoma to the nonmyelosuppressive nitrosourea streptozotocin (STZ) has been observed. The authors therefore studied the effects of combined therapy with BLM, MTX, and STZ in patients with epidermoid carcinoma of the lung.

UR - http://www.scopus.com/inward/record.url?scp=0017853567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017853567&partnerID=8YFLogxK

M3 - Article

C2 - 75065

AN - SCOPUS:0017853567

SN - 0361-5960

VL - 62

SP - 155

EP - 157

JO - Cancer Treatment Reports

JF - Cancer Treatment Reports

IS - 1

ER -

Bleomycin, methotrexate, and streptozotocin in epidermoid carcinoma of the lung: An active drug combination with major nonhematologic toxicity

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this